MCOLN1 and early-onset autosomal dominant Alzheimer disease: The beneficial effects of TRPML1 have also been proposed for Alzheimer’s disease (Cen et al., 2024; Somogyi et al., 2023), seizure (Peng et al., 2024), and juvenile neuronal ceroid lipofuscinosis (Wunkhaus et al., 2024).